MedTrace Logo

Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

NCT01385059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-03-07

Study results available
· View outcomes & findings →

Summary

This randomized phase II trial studies how well axitinib works in treating patients with high-risk prostate cancer before undergoing surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving axitinib before surgery may make the tumor smaller and reduce the amount of normal cells that have to be removed

Conditions

  • Stage III Prostate Cancer
  • Stage IV Prostate Cancer

Interventions

DRUG

axitinib

Given PO

PROCEDURE

therapeutic conventional surgery

Undergo prostatectomy and pelvic lymph node dissection

OTHER

enzyme-linked immunosorbent assay

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • Sumanta Pal · City of Hope Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-28
Primary Completion
2013-10-09
Completion
2013-10-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01385059 on ClinicalTrials.gov